Page 2 - Glen Seymour News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Glen seymour. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Glen Seymour Today - Breaking & Trending Today

Sputnik V's Ph III clinical trial results confirm high efficacy, safety

Sputnik V s Ph III clinical trial results confirm high efficacy, safety
Sputnik V s Ph III clinical trial results confirm high efficacy, safety
02 February 2021 | News
Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine’s high efficacy and safety
Source credit: Shutterstock
The Gamaleya National Research Center of Epidemiology and Microbiology of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund (RDIF) announce that the Lancet has published interim results of a Phase III clinical trial of Sputnik V, confirming the vaccine’s high efficacy and safety.
In the interim efficacy analysis of the randomised, double-blind, placebo-controlled clinical trial, where data on 19,866 volunteers were included in the efficacy analysis (14,964 of whom received the vaccine and 4,902 the placebo), the two-dose treatment of Sputnik V administered 21 days apart demonstrated eff ....

United Kingdom , Russian Federation , Cecil Czerkinsky , Alexander Gintsburg , Kirill Dmitriev , Glen Seymour , Gamaleya Research Institute Of Epidemiology , National Institute Of Health , University Of Oxford , Gamaleya National Research Center , Department Of Oncology , Russian Direct Investment Fund , Gamaleya Research Institute , Research Director , National Institute , Gene Therapies , ஒன்றுபட்டது கிஂக்டம் , ரஷ்ய கூட்டமைப்பு , லென் சீமோர் , தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் , பல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட் , துறை ஆஃப் புற்றுநோயியல் , ரஷ்ய நேரடி முதலீடு நிதி , ஆராய்ச்சி இயக்குனர் , தேசிய நிறுவனம் , கீந் சிகிச்சைகள் ,

A vaccine for all mankind: Sputnik V's efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet

A vaccine for all mankind: Sputnik V s efficacy in fighting COVID-19 is validated by internationally peer reviewed data published in The Lancet
In an interim analysis of a Phase III clinical trial, Sputnik V
showed
Efficacy of Sputnik V against COVID-19 was reported at 91.6%.
- Analysis included data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.
- Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8% and did not differ statistically from the 18-60 group.
Sputnik V provides full protection against severe cases of COVID-19. ....

United Kingdom , United States , Bosnia Herzegovina , Russian Federation , Republic Of Guinea , Cecil Czerkinsky , Glen Seymour , Hildegundcj Ertl , David Livermore , Alexander Gintsburg , Kostenloser Wertpapierhandel , Kirill Dmitriev , University Of East Anglia , National Institute Of Health , University Of Oxford , Gamaleya National Research Center , Data Monitoring Committee , Russian Direct Investment Fund , Gamaleya Research Institute Of Epidemiology , Vaccine Immunotherapy Center , Wistar Institute , Department Of Oncology , Independent Data Monitoring , Bosnian Serb Republic , Gamaleya Research Institute , Research Director ,

Startups see new promise in old insight about viruses to stop cancer

Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy. ....

United States , Eteläuomen Läi , Salk Institute , Margaret Duffy , Iconovir Bio , Vincenzo Cerullo , Mark Mccamish , Kerry Fisher , Glen Seymour , Clodagh Oshea , Paul Higham , Greg Delgoffe , Merck Keytruda , Arthur Kuan , Charlotte Casebourne , Oxford Sciences Innovation , Gilead Sciences , Drug Administration , Salk Institute For Biological Sciences , Kissei Pharmaceutical Co , University Of Pittsburgh , Helsinki University , Epidarex Capital , Taiho Ventures , Oxford Sciences , Kissei Pharmaceutical ,

RDIF and the Gamaleya Center announce International scientific advisory board on Sputnik V vaccine

RDIF and the Gamaleya Center announce International scientific advisory board on Sputnik V vaccine
Russian Direct Investment Fund
426
Russian Direct Investment Fund 19 January 2021 14:54
The Russian Direct Investment Fund (RDIF, Russia s sovereign wealth fund) and The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya (Gamaleya Center) announce the creation of an International Scientific Advisory Board on the Sputnik V vaccine – the world s first registered vaccine against coronavirus.
Leading scientists in virology, microbiology, genetics and biotechnology fr om Argentina, Croatia, France, Germany, India, Russia, Sweden, UK and USA, representing top research and medical centers, have joined the Board. ....

United States , United Kingdom , Sankt Peterburg , Buenos Aires , Distrito Federal , Cecil Czerkinsky , Carlos Zala , Glen Seymour , Wibke Bayer , Alexander Rumyantsev , Davida Ornelles , Niklas Arnberg , Dragomira Majhen , Sergey Tsarenko , Hildegundcj Ertl , Ronald Rodriguez , Vasanthapuram Ravi , Denis Logunov , David Livermore , Alexander Gintsburg , Kirill Dmitriev , Science Of The Gamaleya Center , School Of Medicine , University Of East Anglia , Dmitry Rogachev National Research Center , National Research Center ,

Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials

COVID-19 cases continue to escalate worldwide
The original announcement by the National Research Council of Canada is available at bit.ly/2JRa4fQ.
BOLD-100 is a first-in-class ruthenium-based small molecule drug which selectively inhibits stress-induced upregulation of the chaperone protein GRP78. Currently, the investigational treatment is in a Phase 1b clinical trial in gastrointestinal cancer. In cancer, GRP78 plays a critical role in resistance, survival and proliferation, whereas in viral infections, GRP78 plays a critical role in host recognition, viral entry and viral replication. Preclinical studies have repeatedly demonstrated BOLD-100 has a robust antiviral response against COVID-19.
We are thankful to have this support from NRC IRAP to continue developing BOLD-100 as an antiviral stated Mark Bazett, PhD, Director of Preclinical Development of Bold Therapeutics. We look forward to completing the next required set of nonclinical and manufacturing studies so ....

South Africa , United Kingdom , British Columbia , Mark Bazett , E Russell Mcallister , Glen Seymour , Stephen Barr , Ted Steiner , Preclinical Development Of Bold Therapeutics , Bold Therapeutics Inc , University Of Oxford , Phd Western University , Md University Of British Columbia , National Research Council Of Canada , University Of Ottawa , Bold Therapeutics , National Research Council , Canada Industrial Research Assistance Program , Preclinical Development , Western University , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் கொலம்பியா , ஏ ரஸ்ஸல் மக்யாலிஸ்டர் , லென் சீமோர் , ஸ்டீபன் பார் , டெட் ஸ்டீனர் ,